Global Drugs for Treating Mental Disorders Market Growth (Status and Outlook) 2025-2031

According to this study, the global Drugs for Treating Mental Disorders market size will reach US$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Drugs for Treating Mental Disorders Industry Forecast” looks at past sales and reviews total world Drugs for Treating Mental Disorders sales in 2024, providing a comprehensive analysis by region and market sector of projected Drugs for Treating Mental Disorders sales for 2025 through 2031. With Drugs for Treating Mental Disorders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Treating Mental Disorders industry.

This Insight Report provides a comprehensive analysis of the global Drugs for Treating Mental Disorders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drugs for Treating Mental Disorders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Treating Mental Disorders market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Treating Mental Disorders and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Treating Mental Disorders.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Treating Mental Disorders market by product type, application, key players and key regions and countries.

Segmentation by Type:
Tablets
Capsule
Injection
Solution
Other

Segmentation by Application:
Antipsychotics
Antidepressants
Antianxiety (Anxiolyitcs)
Anti-Seizure Medications
Stimulants
Cognitive Disorders And Dementia
Sleep Disorder Treatments
Substance Abuse Treatments
Hypnosis And Tranquilizers
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson and Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz (Novartis)
Hansoh Pharmaceutical
WATSON Pharmaceuticals
Zhejiang Langhua Pharmaceuticals
Forest Laboratories
H.Lundbeck A/S
Amneal Pharmaceuticals
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Hikma Pharmaceuticals
Lupin Limited
Prinston Pharmaceutical
STI Pharma

Please note: The report will take approximately 2 business days to prepare and deliver. Show more